GWM
INKT icon

Greenwich Wealth Management’s MiNK Therapeutics INKT Stock Holding History

Greenwich Wealth Management’s Portfolio INKT Stock Details INKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-1,081
Closed -$8K – 248
2024
Q4 		$8K Hold
1,081
– – ﹤0.01% 255
2024
Q3 		$8K Buy
+1,081
New +$9.17K ﹤0.01% 247

Other funds holding INKT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LF
Longbow Finance Lutry, Switzerland $782M AUM 48.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
C
Covestor London, United Kingdom $173M AUM 56.91% 1-Year Est. Return

Greenwich Wealth Management's INKT Position: Q1 2025 in Review

Greenwich Wealth Management sold out of MiNK Therapeutics (INKT) in Q1 2025, closing a stake of 1,081 shares — an estimated $8K sold.

Greenwich Wealth Management first reported a position in INKT in Q3 2024 and held it in 2 quarters. The position peaked at $8K in Q4 2024. 17 funds tracked by Wall St. Rank hold INKT as of Q1 2025.

  • Greenwich Wealth Management reported no remaining MiNK Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Greenwich Wealth Management sold 1,081 MiNK Therapeutics shares in Q1 2025, an estimated $8K.
  • Greenwich Wealth Management first reported a position in MiNK Therapeutics in Q3 2024 and held it in 2 quarters.
  • Greenwich Wealth Management's MiNK Therapeutics position peaked at $8K in Q4 2024.
  • 17 funds tracked by Wall St. Rank held MiNK Therapeutics as of Q1 2025.

Based on Greenwich Wealth Management's 13F filing for Q1 2025, filed 12 May 2025.